Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS‐HF trial
Scott D Solomon
(1, 2, 3)
,
John W Ostrominski
(1, 2, 3)
,
Muthiah Vaduganathan
(1, 2, 3)
,
Brian Claggett
(1, 2, 3)
,
Pardeep S Jhund
(4)
,
Akshay S Desai
(1, 2, 3)
,
Carolyn S.P. Lam
(5, 6)
,
Bertram Pitt
(7)
,
Michele Senni
(8)
,
Sanjiv J Shah
(9)
,
Adriaan A Voors
(10)
,
Faiez Zannad
(11, 12, 13, 14)
,
Imran Zainal Abidin
(15)
,
Marco Antonio Alcocer-Gamba
(16)
,
John J Atherton
(17, 18)
,
Johann Bauersachs
(19)
,
Chang‐sheng Ma
(20)
,
Chern‐en Chiang
(21)
,
Ovidiu Chioncel
(22)
,
Vijay Chopra
(23)
,
Josep Comin-Colet
(24, 25)
,
Gerasimos Filippatos
(26, 27)
,
Cândida Fonseca
(28, 29)
,
Grzegorz Gajos
(30)
,
Sorel Goland
(31)
,
Eva Goncalvesová
(32)
,
Seok‐min Kang
(33)
,
Tzvetana Katova
(34)
,
Mikhail N Kosiborod
(35, 36)
,
Gustavs Latkovskis
(37)
,
Alex Pui‐wai Lee
(38)
,
Gerard C.M. Linssen
(39)
,
Guillermo Llamas-Esperón
(40)
,
Vyacheslav Mareev
(41)
,
Felipe A Martinez
(42)
,
Vojtěch Melenovský
(43)
,
Béla Merkely
(44)
,
Savina Nodari
(45)
,
Mark C Petrie
(46, 47)
,
Clara Inés Saldarriaga
(48)
,
Jose Francisco Kerr Saraiva
(49)
,
Naoki Sato
(50)
,
Morten Schou
(51)
,
Kavita Sharma
(52)
,
Richard Troughton
(53)
,
Jacob A Udell
(54)
,
Heikki Ukkonen
(55)
,
Orly Vardeny
(56)
,
Subodh Verma
(57, 58)
,
Dirk von Lewinski
(59)
,
Leonid G Voronkov
(60)
,
Mehmet Birhan Yilmaz
(61)
,
Shelley Zieroth
(62)
,
James Lay-Flurrie
(63)
,
Ilse van Gameren
(64)
,
Flaviana Amarante
(64)
,
Prabhakar Viswanathan
(64)
,
John J.V. McMurray
(46, 47)
1
Brigham and Women's Hospital [Boston]
2 HMS - Harvard Medical School [Boston]
3 BWH - Brigham & Women’s Hospital [Boston]
4 BHF GCRC - British Heart Foundation Glasgow Cardiovascular Research Centre
5 NHCS - National Heart Centre Singapore
6 Duke-NUS Medical School [Singapore]
7 University of Michigan [Ann Arbor]
8 UNIMIB - Università degli Studi di Milano-Bicocca = University of Milano-Bicocca
9 Feinberg School of Medicine
10 UMCG - University Medical Center Groningen [Groningen]
11 DCAC - Défaillance Cardiovasculaire Aiguë et Chronique
12 CIC-P - Centre d'investigation clinique plurithématique Pierre Drouin [Nancy]
13 INI-CRCT - Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy]
14 Cardiovascular & Renal Clinical Trialists - CRCT - French-Clinical Research Infrastructure Network - F-CRIN [Paris]
15 UM - University of Malaya = Universiti Malaya [Kuala Lumpur, Malaisie]
16 Centro de Estudios Clínicos de Querétaro
17 Royal Brisbane and Women's Hospital
18 The University of Queensland
19 MHH - Medizinische Hochschule Hannover = Hannover Medical School
20 Beijing Anzhen Hospital
21 Taipei Veterans general hospital
22 Emergency Institute for Cardiovascular Diseases “Prof. Dr. C.C. Iliescu” [Bucharest, Romania]
23 MSH - MAX Superspecialty Hospital [Saket, New Delhi, India]
24 IDIBELL - Institut d'Investigació Biomèdica de Bellvitge = Bellvitge Biomedical Research Institute
25 UB - Universitat de Barcelona
26 NKUA - National and Kapodistrian University of Athens
27 “Attikon” University Hospital
28 EPE - Hospital de S. Francisco Xavier
29 NOVA - Universidade Nova de Lisboa = NOVA University Lisbon
30 Jagiellonian University - Medical College
31 Kaplan Medical Center [Rehovot, Israel]
32 NICD - National Institute of Cardiovascular Diseases [Bratislava, Slovak Republic]
33 Severance Hospital
34 ICCU, National Cardiology Hospital, Bulgaria
35 Saint Luke's Mid America Heart Institute
36 UMKC - University of Missouri [Kansas City]
37 Pauls Stradins Clinical University Hospital, Latvia
38 CUHK - The Chinese University of Hong Kong [Hong Kong]
39 Hospital Group Twente
40 Hospital Cardiologico Aguascalientes
41 MSU - Lomonosov Moscow State University
42 Universidad Nacional de Córdoba [Argentina]
43 IKEM - Institute for Clinical and Experimental Medicine
44 Semmelweis University [Budapest]
45 University of Brescia and ASST 'Spedali Civili' Hospital
46 BHF - GCRC - British Heart Foundation - Glasgow Cardiovascular Research Center,
47 University of Glasgow
48 Clínica Santa María
49 Instituto de Pesquisa Clínica de Campinas
50 Kawaguchi Cardiovascular and Respiratory Hospital
51 University Hospital Herlev Gentofte
52 Johns Hopkins University School of Medicine [Baltimore]
53 University of Otago [Dunedin, Nouvelle-Zélande]
54 Women's College Hospital and Peter Munk Cardiac Centre
55 TYKS - Turku University Hospital
56 UMN - University of Minnesota System
57 St. Michael's Hospital
58 University of Toronto
59 Medical University of Graz
60 National Academy of Medical Sciences of Ukraine
61 Dokuz Eylul University Medical Faculty
62 University of Manitoba [Winnipeg]
63 Bayer plc, Research & Development
64 Pharmaceuticals Research & Development, Bayer AG
2 HMS - Harvard Medical School [Boston]
3 BWH - Brigham & Women’s Hospital [Boston]
4 BHF GCRC - British Heart Foundation Glasgow Cardiovascular Research Centre
5 NHCS - National Heart Centre Singapore
6 Duke-NUS Medical School [Singapore]
7 University of Michigan [Ann Arbor]
8 UNIMIB - Università degli Studi di Milano-Bicocca = University of Milano-Bicocca
9 Feinberg School of Medicine
10 UMCG - University Medical Center Groningen [Groningen]
11 DCAC - Défaillance Cardiovasculaire Aiguë et Chronique
12 CIC-P - Centre d'investigation clinique plurithématique Pierre Drouin [Nancy]
13 INI-CRCT - Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy]
14 Cardiovascular & Renal Clinical Trialists - CRCT - French-Clinical Research Infrastructure Network - F-CRIN [Paris]
15 UM - University of Malaya = Universiti Malaya [Kuala Lumpur, Malaisie]
16 Centro de Estudios Clínicos de Querétaro
17 Royal Brisbane and Women's Hospital
18 The University of Queensland
19 MHH - Medizinische Hochschule Hannover = Hannover Medical School
20 Beijing Anzhen Hospital
21 Taipei Veterans general hospital
22 Emergency Institute for Cardiovascular Diseases “Prof. Dr. C.C. Iliescu” [Bucharest, Romania]
23 MSH - MAX Superspecialty Hospital [Saket, New Delhi, India]
24 IDIBELL - Institut d'Investigació Biomèdica de Bellvitge = Bellvitge Biomedical Research Institute
25 UB - Universitat de Barcelona
26 NKUA - National and Kapodistrian University of Athens
27 “Attikon” University Hospital
28 EPE - Hospital de S. Francisco Xavier
29 NOVA - Universidade Nova de Lisboa = NOVA University Lisbon
30 Jagiellonian University - Medical College
31 Kaplan Medical Center [Rehovot, Israel]
32 NICD - National Institute of Cardiovascular Diseases [Bratislava, Slovak Republic]
33 Severance Hospital
34 ICCU, National Cardiology Hospital, Bulgaria
35 Saint Luke's Mid America Heart Institute
36 UMKC - University of Missouri [Kansas City]
37 Pauls Stradins Clinical University Hospital, Latvia
38 CUHK - The Chinese University of Hong Kong [Hong Kong]
39 Hospital Group Twente
40 Hospital Cardiologico Aguascalientes
41 MSU - Lomonosov Moscow State University
42 Universidad Nacional de Córdoba [Argentina]
43 IKEM - Institute for Clinical and Experimental Medicine
44 Semmelweis University [Budapest]
45 University of Brescia and ASST 'Spedali Civili' Hospital
46 BHF - GCRC - British Heart Foundation - Glasgow Cardiovascular Research Center,
47 University of Glasgow
48 Clínica Santa María
49 Instituto de Pesquisa Clínica de Campinas
50 Kawaguchi Cardiovascular and Respiratory Hospital
51 University Hospital Herlev Gentofte
52 Johns Hopkins University School of Medicine [Baltimore]
53 University of Otago [Dunedin, Nouvelle-Zélande]
54 Women's College Hospital and Peter Munk Cardiac Centre
55 TYKS - Turku University Hospital
56 UMN - University of Minnesota System
57 St. Michael's Hospital
58 University of Toronto
59 Medical University of Graz
60 National Academy of Medical Sciences of Ukraine
61 Dokuz Eylul University Medical Faculty
62 University of Manitoba [Winnipeg]
63 Bayer plc, Research & Development
64 Pharmaceuticals Research & Development, Bayer AG
Scott D Solomon
- Fonction : Auteur
- PersonId : 1373682
- ORCID : 0000-0003-3698-9597
John W Ostrominski
- Fonction : Auteur
- PersonId : 1383324
- ORCID : 0000-0002-2866-9414
Résumé
Aims To describe the baseline characteristics of participants in the FINEARTS‐HF trial, contextualized with prior trials including patients with heart failure (HF) with mildly reduced and preserved ejection fraction (HFmrEF/HFpEF). The FINEARTS‐HF trial is comparing the effects of the non‐steroidal mineralocorticoid receptor antagonist finerenone with placebo in reducing cardiovascular death and total worsening HF events in patients with HFmrEF/HFpEF. Methods and results Patients with symptomatic HF, left ventricular ejection fraction (LVEF) ≥40%, estimated glomerular filtration rate ≥ 25 ml/min/1.73 m 2 , elevated natriuretic peptide levels and evidence of structural heart disease were enrolled and randomized to finerenone titrated to a maximum of 40 mg once daily or matching placebo. We validly randomized 6001 patients to finerenone or placebo (mean age 72 ± 10 years, 46% women). The majority were New York Heart Association functional class II (69%). The baseline mean LVEF was 53 ± 8% (range 34–84%); 36% of participants had a LVEF <50% and 64% had a LVEF ≥50%. The median N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) was 1041 (interquartile range 449–1946) pg/ml. A total of 1219 (20%) patients were enrolled during or within 7 days of a worsening HF event, and 3247 (54%) patients were enrolled within 3 months of a worsening HF event. Compared with prior large‐scale HFmrEF/HFpEF trials, FINEARTS‐HF participants were more likely to have recent (within 6 months) HF hospitalization and greater symptoms and functional limitations. Further, concomitant medications included a larger percentage of sodium–glucose cotransporter 2 inhibitors and angiotensin receptor–neprilysin inhibitors than previous trials. Conclusions FINEARTS‐HF has enrolled a broad range of high‐risk patients with HFmrEF and HFpEF. The trial will determine the safety and efficacy of finerenone in this population.
Domaines
Sciences du Vivant [q-bio]
Fichier principal
European J of Heart Fail - 2024 - Solomon - Baseline characteristics of patients with heart failure with mildly reduced or.pdf (1.44 Mo)
Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte